Some researchers therefore emphasize that SGLT1/2 dual inhibitors provide greater cardiac benefit and heart failure prevention compared to selective SGLT2is [141], but the role of SGLT1 inhibition in terms of cardiovascular benefits has a fair share of contradictory reports. This evidence concerns the gene SLC5A1 and heart failure.